A detailed history of Farther Finance Advisors, LLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 30 shares of PCRX stock, worth $436. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30
Previous 4 650.0%
Holding current value
$436
Previous $117,000 629.91%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$25.5 - $31.51 $663 - $819
26 Added 650.0%
30 $854,000
Q1 2024

May 13, 2024

SELL
$27.7 - $35.48 $304 - $390
-11 Reduced 73.33%
4 $117,000
Q4 2023

Feb 14, 2024

BUY
$26.32 - $34.31 $973 - $1,269
37 Added 740.0%
42 $1.42 Million
Q3 2023

Nov 13, 2023

BUY
$30.68 - $40.09 $153 - $200
5 New
5 $153,000
Q1 2023

May 13, 2024

SELL
$35.53 - $43.38 $959 - $1,171
-27 Reduced 64.29%
15 $612,000
Q1 2023

Sep 12, 2023

BUY
$35.53 - $43.38 $532 - $650
15 New
15 $612,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $666M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.